[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Clinical trial NCT06229366 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06229366
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Prostate Cancer Metastatic Castration-resistant Prostate Cancer Oligometastatic Prostate Carcinoma Hormone Sensitive Prostate Cancer

Start date: 2024-04-03
Primary completion: 2027-09-01
Enrollment: 142

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.